Literature DB >> 7975301

Electrophysiological signs of retinal dopamine deficiency in recently diagnosed Parkinson's disease and a follow up study.

H Ikeda1, G M Head, C J Ellis.   

Abstract

Electrophysiological studies, including electrooculogram (EOG), and simultaneously recorded flash and pattern evoked electroretinograms (FERG and PERG) and visually evoked potentials (FVEP and PVEP) were made in 1988 on 10 newly diagnosed untreated Parkinson's patients at Stage 1 of the Hoehn and Yahr scale. Follow up studies were made on five out of the 10 patients when their disease had progressed to Stage 2 during 1993. The earliest and only sign of abnormality detected in the Stage 1 of Parkinson's patients in 1988 was a delay in the time to reach the peak light rise in the EOG. When the disease had progressed to Stage 2, not only a delay in the time to reach the peak light rise but also a reduction in the amplitude of the peak light rise in the EOG, together with changes in PERG, FERG and PVEPs were demonstrable. These changes observed in PERG, FERG and PVEPs were generally consistent with those reported by previous studies. It is suggested that the reason for the susceptibility of pigment epithelial function to dopamine deficiency in Parkinson's disease may be due to the pigment epithelium being at the extremity of the diffusion pathway from dopamine release sites at the inner plexiform layer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7975301     DOI: 10.1016/0042-6989(94)90248-8

Source DB:  PubMed          Journal:  Vision Res        ISSN: 0042-6989            Impact factor:   1.886


  23 in total

1.  Influence of dopamine deficiency in early Parkinson's disease on the slow stimulation multifocal-ERG.

Authors:  Anja M Palmowski-Wolfe; Maria Timoner Perez; Stefanie Behnke; Gerhard Fuss; Martin Martziniak; Klaus W Ruprecht
Journal:  Doc Ophthalmol       Date:  2006-06-22       Impact factor: 2.379

2.  Retinal dysfunction of contrast processing in major depression also apparent in cortical activity.

Authors:  Emanuel Bubl; Elena Kern; Dieter Ebert; Andreas Riedel; Ludger Tebartz van Elst; Michael Bach
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-01-08       Impact factor: 5.270

Review 3.  A meta-analysis of clinical electro-oculography values.

Authors:  Paul A Constable; David Ngo; Stephen Quinn; Dorothy A Thompson
Journal:  Doc Ophthalmol       Date:  2017-10-10       Impact factor: 2.379

Review 4.  Circadian organization of the mammalian retina: from gene regulation to physiology and diseases.

Authors:  Douglas G McMahon; P Michael Iuvone; Gianluca Tosini
Journal:  Prog Retin Eye Res       Date:  2013-12-12       Impact factor: 21.198

5.  Occipital hypoperfusion in Parkinson's disease without dementia: correlation to impaired cortical visual processing.

Authors:  Y Abe; T Kachi; T Kato; Y Arahata; T Yamada; Y Washimi; K Iwai; K Ito; N Yanagisawa; G Sobue
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

6.  Application of an OCT data-based mathematical model of the foveal pit in Parkinson disease.

Authors:  Yin Ding; Brian Spund; Sofya Glazman; Eric M Shrier; Shahnaz Miri; Ivan Selesnick; Ivan Bodis-Wollner
Journal:  J Neural Transm (Vienna)       Date:  2014-04-20       Impact factor: 3.575

Review 7.  The Retina and Other Light-sensitive Ocular Clocks.

Authors:  Joseph C Besharse; Douglas G McMahon
Journal:  J Biol Rhythms       Date:  2016-04-19       Impact factor: 3.182

Review 8.  Retinopathy in Parkinson Disease.

Authors:  Ivan Bodis-Wollner
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

Review 9.  [The eye as a window to the pathophysiology in Parkinson's syndromes].

Authors:  J Kassubek; A Danek; K Del Tredici-Braak; M W Greenlee; E H Pinkhardt
Journal:  Nervenarzt       Date:  2013-08       Impact factor: 1.214

10.  Little effect of 0.01% atropine eye drops as used in myopia prevention on the pattern electroretinogram.

Authors:  Lisa-Marie Anders; Sven P Heinrich; Wolf A Lagrèze; Lutz Joachimsen
Journal:  Doc Ophthalmol       Date:  2019-01-24       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.